ClinicalTrials.gg
CompletedNCT02304484Updated Mar 19, 2019Results posted

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

A Phase 3 interventional study of Evolocumab in Hypercholesterolemia, sponsored by Amgen. Completed at 126 sites in 29 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
770
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
9th of 36
770 · median 308
Started
2014
with 2 others
Phase 3
22 of 36
none open now
Registered
22nd of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 9th largest by enrollment, is one of 3 that started in 2014, is one of 22 in phase 3, and was the 22nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed week 80 of study 20120153 (NCT01813422).

Exclusion criteria

Exclusion Criteria:

  • Did not complete product in the 20120153 parent study
  • Have an unstable medical condition, in the judgment of the investigator
  • Known sensitivity to any of the products to be administered during dosing
  • Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
770 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants received 420 mg evolocumab once a month for up to 2 years.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection once a month

    Also known as: AMG 145, Repatha

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe or medically significant AE, Grade 4 = Life-threatening consequences, and Grade 5 = death related to AE. An adverse device effect was defined as any adverse event related to the use of a medical device (autoinjector/pen or automated mini doser \[AMD\]), including but not limited to, AEs resulting from insufficient or inadequate Instructions for Use, AEs resulting from any malfunction of the device, or AEs resulting from use error or from intentional misuse of the device.

    Time frame: From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.

Secondary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline (of study 20120153) and weeks 0, 4, 12, 24, 36, 48, 52, 76, and 104 of study 20140128

07

Results

Posted Mar 19, 2019

Participant flow

This study was conducted at 126 centers in 29 countries in the regions of Europe, North America, Asia Pacific, and Latin America. Participants were enrolled from 24 November 2014 to 31 August 2016.

Participant flow — Overall Study
MilestoneEvolocumab
Started770
Completed745
Not completed25
Withdrew: Death9
Withdrew: Withdrawal by subject14
Withdrew: Lost to follow-up2

Outcome measures

PrimaryNumber of Participants With Adverse Events

The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe or medically significant AE, Grade 4 = Life-threatening consequences, and Grade 5 = death related to AE. An adverse device effect was defined as any adverse event related to the use of a medical device (autoinjector/pen or automated mini doser \[AMD\]), including but not limited to, AEs resulting from insufficient or inadequate Instructions for Use, AEs resulting from any malfunction of the device, or AEs resulting from use error or from intentional misuse of the device.

Time frame:
From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsEvolocumab
Any adverse event526
Adverse events ≥ Grade 2415
Adverse events ≥ Grade 3206
Adverse events ≥ Grade 438
Serious adverse events153
AEs leading to discontinuation of evolocumab14
Fatal adverse events6
Device-related adverse events12
Device-related adverse events ≥ Grade 22
Device-related adverse events ≥ Grade 31
Device-related adverse events ≥ Grade 40
Serious device-related adverse events0
SecondaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time frame:
Baseline (of study 20120153) and weeks 0, 4, 12, 24, 36, 48, 52, 76, and 104 of study 20140128
Reported as:
Mean · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
percent changeEvolocumab
Percent change from baseline to week 0-21.52 ± 40.49
Percent change from baseline to week 4-57.23 ± 22.19
Percent change from baseline to week 12-58.54 ± 25.60
Percent change from baseline to week 24-55.26 ± 28.51
Percent change from baseline to week 36-51.72 ± 30.34
Percent change from baseline to week 48-53.65 ± 28.72
Percent change from baseline to week 52-51.30 ± 28.48
Percent change from baseline to week 76-51.73 ± 32.49
Percent change from baseline to week 104-47.94 ± 36.49

Adverse events

Collected over Total deaths are reported from the 1st dose of evolocumab up to the end of study; adverse events are reported from the 1st dose of evolocumab up to 30 days after the last dose of study drug or end of study, whichever was earlier. The median (minimum, maximum) duration of treatment was 23.7 (0.4, 24.6) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evolocumab9/770 (1.2%)153/770 (19.9%)49/770 (6.4%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventEvolocumab
Angina pectorisCardiac disorders13/770
Non-cardiac chest painGeneral disorders6/770
Angina unstableCardiac disorders5/770
Atrial fibrillationCardiac disorders5/770
OsteoarthritisMusculoskeletal and connective tissue disorders5/770
Acute myocardial infarctionCardiac disorders4/770
Coronary artery diseaseCardiac disorders4/770
Chest painGeneral disorders4/770
PneumoniaInfections and infestations4/770
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/770
Most frequent other events
Most frequent other events
EventEvolocumab
HypertensionVascular disorders49/770

Baseline characteristics

All enrolled participants. Baseline is defined as parent study 20120153 baseline.

Age, Continuous
Age, Continuous(years)Evolocumab
Mean59.5 ± 8.8
Age, Customized
Age, Customized(Participants)Evolocumab
18 - 64 years536
≥ 65 years234
Sex: Female, Male
Sex: Female, Male(Participants)Evolocumab
Female202
Male568
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Evolocumab
Hispanic or Latino38
Not Hispanic or Latino732
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Evolocumab
American Indian or Alaska Native1
Asian19
Black or African American5
Native Hawaiian or Other Pacific Islander1
White729
Multiple11
Other4
Low-density Lipoprotein Cholesterol (LDL-C) Concentration
Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)Evolocumab
Mean92.2 ± 27.3
08

Study locations

126 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Long Beach, California 90822, United States
  • Research Site
    San Diego, California 92161, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Bethesda, Maryland 20814, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Bay City, Michigan 48708, United States
  • Research Site
    Midland, Michigan 48670, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Saint Cloud, Minnesota 56303, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    Ridgewood, New Jersey 07450, United States
  • Research Site
    Fargo, North Dakota 58122, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Toledo, Ohio 43614, United States
  • Research Site
    Oak Ridge, Tennessee 37830, United States
  • Research Site
    Amarillo, Texas 79106, United States
  • Research Site
    Dallas, Texas 75216, United States
  • Research Site
    Wichita Falls, Texas 76301, United States
  • Research Site
    La Plata, Buenos Aires B1906EHD, Argentina
  • Research Site
    Cordoba, Córdoba X5016KEH, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    Córdoba, X5021FPI, Argentina
  • Research Site
    Liverpool, New South Wales 2170, Australia
  • Research Site
    New Lambton Heights, New South Wales 2305, Australia
  • Research Site
    Chermside, Queensland 4032, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Fullarton, South Australia 5063, Australia
  • Research Site
    Epping, Victoria 3076, Australia
  • Research Site
    Footscray, Victoria 3011, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Antwerpen, 2020, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Lodelinsart, 6042, Belgium
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90620-001, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Victoria, British Columbia V8R 4R2, Canada
  • Research Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • Research Site
    St. Johns, Newfoundland and Labrador A1B 3V6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Toronto, Ontario M5B 1W8, Canada
  • Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Research Site
    Laval, Quebec H7M 3L9, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Temuco, Cautín 4781156, Chile
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Zlin, 762 75, Czechia
  • Research Site
    Besancon cedex, 25030, France
  • Research Site
    Chambray les Tours, 37170, France
  • Research Site
    Marseille cedex 5, 13385, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Pessac Cedex, 33604, France
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Athens, 14561, Greece
  • Research Site
    Heraklion, 71110, Greece
  • Research Site
    Budapest, 1023, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Budapest, 1134, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Reykjavik, 101, Iceland
  • Research Site
    Galway, Ireland
  • Research Site
    Hadera, 38100, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Novara, 28100, Italy
  • Research Site
    Rozzano MI, 20089, Italy
  • Research Site
    Sesto San Giovanni (MI), 20099, Italy
  • Research Site
    Torino, 10154, Italy
  • Research Site
    Daejeon, 301-723, Korea, Republic of
  • Research Site
    Seongnam-si, Gyeonggi-do, 463-707, Korea, Republic of
  • Research Site
    Seoul, 130-872, Korea, Republic of
  • Research Site
    Seoul, 156-707, Korea, Republic of
  • Research Site
    Kuantan, Pahang 25100, Malaysia
  • Research Site
    Penang, 10050, Malaysia
  • Research Site
    Guadalajara, Jalisco 44670, Mexico
  • Research Site
    San Luis Potosi, San Luis Potosí 78240, Mexico
  • Research Site
    Culiacan, Sinaloa 80230, Mexico
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Alkmaar, 1815 JD, Netherlands
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Amsterdam, 1091 AC, Netherlands
  • Research Site
    Leeuwarden, 8934 AD, Netherlands
  • Research Site
    Nijmegen, 6532 SZ, Netherlands
  • Research Site
    Rotterdam, 3079 DZ, Netherlands
  • Research Site
    Tilburg, 5042 AD, Netherlands
  • Research Site
    Utrecht, 3508 GZ, Netherlands

Showing the first 100 of 126 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Mar 2018, 39 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 39 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2014
First posted
Dec 2, 2014
StartActual
Nov 24, 2014
Primary completionActual
Mar 9, 2018
CompletionActual
Mar 9, 2018
Results first posted
Mar 19, 2019
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02304484
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 2, 2014
Start date
Nov 24, 2014
Primary completion
Mar 9, 2018
Completion
Mar 9, 2018
Results posted
Mar 19, 2019
Last update
Mar 19, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion